Can a Five-Part vaccine bolster protection against three serious infections?

NCT ID NCT06708286

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This trial evaluates a new five-component vaccine (Tdcp) designed to protect against diphtheria, tetanus, and pertussis (whooping cough). It includes about 1,820 participants aged 7 and older, who receive either the experimental vaccine or a control vaccine. The study measures how well the vaccine triggers an immune response and monitors for any side effects, aiming to see if this new formulation is safe and effective for older age groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tdcp vaccine (tetanus, reduced diphtheria, and acellular pertussis, five components)
What this could lead to
If successful, this vaccine could offer stronger or longer-lasting protection against diphtheria, tetanus, and whooping cough for older children and adults.
What could go wrong
The trial is in early-to-mid stages, so the vaccine may not prove more effective than existing ones. As with any vaccine, there is a risk of side effects like injection-site reactions or fever.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIPHTHERIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Kaihua County Center for Disease Control and Prevention

    Kaihua, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.